Towards principled design of cancer nanomedicine to accelerate clinical translation

Souri, Maryam; Soltani, M.; Kashkooli, Farshad Moradi; Shahvandi, Mohammad Kiani; Chiani, Mohsen; Shariati, Fatemeh Sadat; Mehrabi, Mohammad Reza; Munn, Lance L.

doi:10.1016/j.mtbio.2022.100208

Cited by 64 publications

(55 citation statements)

References 396 publications

(444 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, iron oxide (Fe 3 O 4 ) nanoparticles are the classic ones used in both T 1 -weighted and T 2 -weighted MRI (Ma et al, 2017;Shen et al, 2017). The ultrasmall ones with diameters smaller than 5 nm are used as positive contrast agents for T 1 -weighted MRI, while the bigger ones larger than 10 nm are potentially used as negative contrast agents for T 2 -weighted MRI due to their high r 2 relaxivity (Hu et al, 2011;Lee and Hyeon, 2012;Lee et al, 2015;Martinkova et al, 2018;Dadfar et al, 2019;Souri et al, 2022). Nevertheless, one major hurdle is that Fe 3 O 4 nanoparticles easily aggregate and precipitate in the solution (Yu et al, 2006;Kim et al, 2011); the other one is that the use of bare Fe 3 O 4 nanoparticles only benefits from passive targeting as a result of the EPR effect in leaky vasculature and poor lymphatic drainage (Maeda, 2010;Barreto et al, 2011;Luo et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Hyaluronic Acid–Stabilized Fe3O4 Nanoparticles for Promoting In Vivo Magnetic Resonance Imaging of Tumors

Zhang

Lou

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

The use of iron oxide (Fe3O4) nanoparticles as novel contrast agents for magnetic resonance imaging (MRI) has attracted great interest due to their high r2 relaxivity. However, both poor colloidal stability and lack of effective targeting ability have impeded their further expansion in the clinics. Here, we reported the creation of hyaluronic acid (HA)-stabilized Fe3O4 nanoparticles prepared by a hydrothermal co-precipitation method and followed by electrostatic adsorption of HA onto the nanoparticle surface. The water-soluble HA functions not only as a stabilizer but also as a targeting ligand with high affinity for the CD44 receptor overexpressed in many tumors. The resulting HA-stabilized Fe3O4 nanoparticles have an estimated size of sub-20 nm as observed by transmission electron microscopy (TEM) imaging and exhibited long-term colloidal stability in aqueous solution. We found that the nanoparticles are hemocompatible and cytocompatible under certain concentrations. As verified by quantifying the cellular uptake, the Fe3O4@HA nanoparticles were able to target a model cell line (HeLa cells) overexpressing the CD44 receptor through an active pathway. In addition, we showed that the nanoparticles can be used as effective contrast agents for MRI both in vitro in HeLa cells and in vivo in a xenografted HeLa tumor model in rodents. We believe that our findings shed important light on the use of active targeting ligands to improve the contrast of lesion for tumor-specific MRI in the nano-based diagnosis systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Hyaluronic Acid–Stabilized Fe3O4 Nanoparticles for Promoting In Vivo Magnetic Resonance Imaging of Tumors

Zhang

Lou

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Then, after calcium phosphate (CaPO) mineralization, the zeta potential decreased to −10.5 mV. Finally, the RGD polypeptide with the PEG chain (NHS-PEG-RGD) was used to modify DOX-loaded CaPO (CaPO/DOX) NPs to improve the tumor-targeting efficiency since RGD has been extensively used in targeting design and has been proven to feature an excellent effect on tumor targeting. , Meanwhile, PEG functionalization is beneficial for shielding the negative charge of NPs (zeta potential from −10.5 to −2.3 mV), preventing non-specific adsorption from various proteins and avoiding phagocytosis by peritoneal macrophages. ,, The as-prepared RGD-CaPO/DOX NPs were pink freeze-dried powder, which could be uniformly dispersed in the aqueous phase, potentiating the clinical utilization (Figure S1, Supporting Information). TEM images showed that RGD-CaPO/DOX were monodispersed NPs with an average particles size of 122.4 nm (Figure C,D).…”

Section: Resultsmentioning

confidence: 99%

Engineering Chemotherapeutic-Augmented Calcium Phosphate Nanoparticles for Treatment of Intraperitoneal Disseminated Ovarian Cancer

Qiu

Chen

Huang

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Ovarian cancer is a common gynecologic malignancy with a high fatality rate. Intraperitoneal chemotherapy has been proved as an efficient clinical treatment for disseminated ovarian cancer. However, there are limitations for conventional small molecule drugs to achieve an ideal therapeutic effect. Herein, a synergistic treatment for intraperitoneally disseminated ovarian cancer was achieved by Arg-Gly-Asp (RGD)-modified amorphous calcium phosphate loading with doxorubicin (designated as RGD-CaPO/DOX). The engineered calcium-involved nanomedicine augmented the therapeutic effect of DOX by aggravating endoplasmic reticulum stress, calcium overload, and mitochondrial dysfunction, ultimately triggering mitochondrial apoptosis in the SKOV3 (human ovarian cancer) cell line. In an intraperitoneally disseminated tumor model, RGD modification and the weak negative surface potential of the NPs were beneficial for intraperitoneal retention and tumor targeting. Moreover, intraperitoneal injection of RGD-CaPO/DOX NPs resulted in a favorable antitumor effect. The mean survival time of SKOV3-bearing mice was significantly extended from 29 to 59 days with negligible toxicity. Therefore, this study has been designed to provide an effective chemotherapeutic-augmented treatment for intraperitoneally disseminated ovarian cancer.

show abstract

“…Removal of nanoparticles from the circulation by these mechanisms reduces their bioavailability, which also reduces their therapeutic efficacy. The ability to manipulate the physicochemical properties of nanoparticles allows these barriers to be overcome [ 247 ]. Furthermore, surface modifications of nanoparticles by ligands with specific targets, it is possible to significantly prevent the attachment of nanoparticles to normal cells and subsequently the toxicity caused by the particles [ 28 ].…”

Section: Treatmentmentioning

confidence: 99%

“…The second stage of clinical failure of nanoparticles can be attributed to the lack of sufficient confidence to invest in this field. This has led to many preclinical studies not being developed for clinical trials due to a lack of funding [ 247 ]. Many researchers believe that the epidemic of COVID-19 becomes a chronic and seasonal disease.…”

Section: Concluding Remarkmentioning

confidence: 99%

Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment

et al. 2022

Self Cite

View full text Add to dashboard Cite

Following the announcement of the outbreak of COVID-19 by the World Health Organization, unprecedented efforts were made by researchers around the world to combat the disease. So far, various methods have been developed to combat this “virus” nano enemy, in close collaboration with the clinical and scientific communities. Nanotechnology based on modifiable engineering materials and useful physicochemical properties has demonstrated several methods in the fight against SARS-CoV-2. Here, based on what has been clarified so far from the life cycle of SARS-CoV-2, through an interdisciplinary perspective based on computational science, engineering, pharmacology, medicine, biology, and virology, the role of nano-tools in the trio of prevention, diagnosis, and treatment is highlighted. The special properties of different nanomaterials have led to their widespread use in the development of personal protective equipment, anti-viral nano-coats, and disinfectants in the fight against SARS-CoV-2 out-body. The development of nano-based vaccines acts as a strong shield in-body. In addition, fast detection with high efficiency of SARS-CoV-2 by nanomaterial-based point-of-care devices is another nanotechnology capability. Finally, nanotechnology can play an effective role as an agents carrier, such as agents for blocking angiotensin-converting enzyme 2 (ACE2) receptors, gene editing agents, and therapeutic agents. As a general conclusion, it can be said that nanoparticles can be widely used in disinfection applications outside in vivo. However, in in vivo applications, although it has provided promising results, it still needs to be evaluated for possible unintended immunotoxicity. Reviews like these can be important documents for future unwanted pandemics.

show abstract

Towards principled design of cancer nanomedicine to accelerate clinical translation

Cited by 64 publications

References 396 publications

Hyaluronic Acid–Stabilized Fe3O4 Nanoparticles for Promoting In Vivo Magnetic Resonance Imaging of Tumors

Hyaluronic Acid–Stabilized Fe3O4 Nanoparticles for Promoting In Vivo Magnetic Resonance Imaging of Tumors

Engineering Chemotherapeutic-Augmented Calcium Phosphate Nanoparticles for Treatment of Intraperitoneal Disseminated Ovarian Cancer

Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment

Contact Info

Product

Resources

About